Circulating tumour cells (CTCs) are commonly detected by epithelial markers of cancer cells, such as EpCAM or cytokeratins (CK) ([@bib16]). CTCs have been identified in the peripheral blood (PB) of patients with gastric, colorectal, and breast cancers using multiple epithelial cell-specific markers, for example, CEA, CK-7, and CK-19 ([@bib13], [@bib14]; [@bib11], [@bib12]). However, some CTCs may gain mesenchymal properties through the epithelial-to-mesenchymal transition (EMT), in which the degree of epithelial differentiation is reduced and the expression of mesenchymal genes is induced ([@bib8]). Therefore, detection of tumour cells that have undergone EMT-like changes is hampered when targeting only epithelial marker proteins, leading to false-negative findings. Tumour cells that have undergone EMT-associated changes are able to acquire invasive properties or stem-like characteristics ([@bib17]). Moreover, cancer cells with a fully completed EMT may not be able to form metastases, whereas tumour cells with an intermediate E/M phenotype appear to be the initiators of metastases ([@bib20]). Hence, the discovery of new marker proteins for CTCs with both epithelial and mesenchymal attributes is essential for the identification of a true marker for CTCs with metastatic potential.

*Plastin3* (*PLS3*) is a novel CTC marker in colon cancer and is expressed on tumour cells with epithelial and EMT-associated phenotypes ([@bib21]; [@bib19]). *PLS3* encodes for an actin-bundling protein that may be important for processes enabling tumour cells to form metastases, such as the escape from anoikis, resistance to chemotherapy, increased cancer stemness, and induction of EMT ([@bib21]).

In the current study, we investigated whether *PLS3* was a suitable marker for CTCs and for predicting prognosis in breast cancer. Our data supported the clinical significance of *PLS3* as marker for poor prognosis in lymph node-negative and triple-negative breast cancer cases, emphasising the importance of this molecule.

Materials and methods
=====================

Cultivation of cell lines
-------------------------

MDA-MB-231 cells were maintained in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal calf serum and 2 m[M L]{.smallcaps}-glutamine (Gibco/Life Technologies, Carlsbad, CA, USA) in a humidified atmosphere at 37 °C and 10% CO~2~. All other cells were cultivated as described previously ([@bib2]).

Qualitative reverse transcription--PCR (qRT--PCR)
-------------------------------------------------

RNA was isolated using a NucleoSpin RNA II Kit (Macherey-Nagel, Düren, Germany) followed by cDNA synthesis (First Strand cDNA Synthesis Kit, Thermo Scientific, Waltham, MA, USA). Primers were designed and qRT--PCR was performed as described elsewhere ([@bib21]).

Sample procurement for western blotting
---------------------------------------

Cells were washed with PBS and lysed in lysis mix (9.8 [M]{.smallcaps} urea, 15 m[M]{.smallcaps} EDTA, and 30 m[M]{.smallcaps} Tris). Cell lysates were homogenised and supernatants were then collected. Negative controls (FICOLL-enriched peripheral blood mononuclear cells (PBMCs) from healthy individuals) were isolated to test the specificity of *PLS3*. Protein was purified by precipitation using 600 *μ*l precipitant (component of the 2-D Quant Kit, GE Healthcare, Uppsala, Sweden) per 250 *μ*l sample and coprecipitant (component of the 2-D Quant Kit) in the same amount. Purified proteins were dissolved in 100 *μ*l of 9.8 [M]{.smallcaps} urea and solubilised for 1 h at room temperature. Protein concentrations were determined using a Pierce BCA Protein Assay Kit (Pierce, Rockford, MD, USA) following the manufacturer\'s instructions, with BSA as standard.

Western blotting
----------------

Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 10% polyacrylamide gels. For all analyses, 40 *μ*g of protein was applied. Proteins were transferred to Immobilon-PSQ membranes (Millipore GmbH, Schwalbach, Germany), and nonspecific binding was blocked by incubation in 5% low-fat powdered milk (Roth, Karlsruhe, Germany) in TBST (blocking buffer) with gentle agitation for 1 h. Primary antibodies (rabbit polyclonal anti-PLS3, C15, Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1 : 1000; rabbit monoclonal anti-*α*-tubulin, Cell Signaling Technology, Danvers, MA, USA, 1 : 10 000) were diluted in blocking buffer and incubated with the membrane at 4 °C overnight. Membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Dako, Glostrup, Denmark) diluted 1 : 1500 in blocking buffer. Bands were visualised using ECL Prime Western Blotting Detection Reagent and X-ray films (GE Healthcare). X-ray films were digitised using a GS-700 imaging densitometer (Bio-Rad, Hercules, CA, USA). Densitometric analysis was performed using Quantity One software (Bio-Rad). Each reaction was performed in biological triplicate.

Cell staining (spiking experiments)
-----------------------------------

Cancer cells were spiked into blood from healthy individuals, followed by FICOLL density centrifugation and cytospin preparation (Superfrost Plus, Karl Hecht KG, Sondheim, Germany). The slides were air-dried overnight and stored at −80 °C until processing. Immunocytochemical double staining was performed using anti-pan cytokeratin (panCK) antibodies (AE1/AE3, Dako) together with two different anti-PLS3 antibodies (C15, Santa Cruz Biotechnology (Plastin antibody 1) or PA5-27883, Thermo Scientific (Plastin antibody 2)). Briefly, slides were thawed 30 min before incubation with 4% PFA in PBS. After washing with PBS, cells were permeabilised using 1% Triton X-100 in PBS. Blocking of unspecific binding was performed after two washing steps using 10% AB-Serum (Biotest, Dreieich, Germany) in PBS. Anti-PLS3 antibodies were then added at a dilution of 1 : 100 (10% AB-Serum in PBS) and incubated for 45 min. Subsequently, slides were washed with PBS, and Alexa546 goat anti-rabbit secondary antibodies (Molecular Probes, Eugene, OR, USA) were applied for 45 min (diluted 1 : 200 in 10% AB-Serum in PBS). After further washing steps, the panCK cocktail (AE1/AE3) was applied (1 : 300) and incubated for 45 min, followed by additional washing steps. Slides were covered with Vectashield Mounting Medium containing DAPI (Vector Laboratories, Burlingame, CA, USA).

Staining controls were run in parallel using dilution media instead of the primary and secondary antibodies. Slides were evaluated manually using an Axioplan 2 microscope (Carl Zeiss AG, Oberkochen, Germany).

PB samples from breast cancer cases and healthy controls
--------------------------------------------------------

A total of 594 patients with breast cancer underwent resection of the primary tumour at the Kyushu University Beppu Hospital, Kyushu Cancer Center or affiliated hospitals from 2000 to 2008. The average age of the patients was 55.2 years, and tumour stages I, II, III, and IV were observed (34.1%, 58.2%, 6.2%, and 1.5%, respectively). Of the patients, 39.3% were positive for lymph node metastases and 1.5% were positive for distant metastases ([Table 1](#tbl1){ref-type="table"}). PB sample sets were used to clarify the prognostic value of *PLS3* as a novel marker for CTCs. As a training set, 298 PB samples were obtained before surgery (average age 56.3 years). Oestrogen receptor (ER), progesterone receptor (PgR), and HER2 were examined using usual immunohistochemical methods. Subtypes were defined as follows: luminal A, ER and/or PgR (+), HER2 (−); luminal B, ER and/or PgR (+), HER2 (+); HER2 type, ER (−), PgR (−), HER2 (+); triple negative, ER (−), PgR (−), HER2 (−); unclassified type, others ([@bib15]). Luminal A, luminal B, HER2 type, triple-negative type, and unclassified tumour type were positive in 72.9%, 4.7%, 8.0%, 9.7%, and 4.7% of patients, respectively. In addition, 296 patient-derived blood samples were tested as a validation set (average age 55.2 years), with tumour-type distributions as follows: luminal A, 67.2% luminal B, 8.4% HER2 type, 5.1% triple-negative type, 15.2% and unclassified, 4.1%. Patients with stage I--III cancer were evaluated for tumour recurrence by physical examination, and tumour marker testing (CEA and CA15-3) was conducted every 3 months for 3 years and every 6 months for 5 years thereafter. To evaluate disease recurrence, computed tomography or magnetic resonance imaging was applied every 6--12 weeks for 3 years and then every 6 months for up to 5 years after surgery. Postoperative adjuvant therapy was applied based on the international consensus ([@bib4]). Hormonal monotherapy was done on the low-risk patients with ER and/or PgR (+). Adjuvant chemotherapy was added on high-risk patients. Recurrence was determined by imaging or pathological diagnosis of biopsy samples. PB samples from healthy individuals (*n*=25) who had no evidence of any disease by physical examination, blood tests, X-ray, or ultrasound examination were used as a control set. All processed samples were used in accordance with institutional guidelines after obtaining written informed consent from the participants. Postoperative follow-up was performed following the guidelines published by the Japanese Society for Breast Cancer.

Quantitative RT--PCR for PB samples
-----------------------------------

Total RNA was extracted from PB of patients using a PAXgene Blood RNA Kit (Qiagen, Venlo, Netherlands), as previously described ([@bib6]). Gene-specific oligonucleotide primers were designed and qRT--PCR was performed in a LightCycler (Roche Diagnostics, Basel, Switzerland) using the LightCycler-FastStart DNA Master SYBR Green I Kit, as described ([@bib6]).

Statistical analysis
--------------------

The sample sizes of the training and validation sets were calculated using SAS statistics software v. 10 (SAS Institute, Cary, NC, USA) based on the results of a small-scale test (*n*=50) in which a one-sided *P*-value of 0.025 would have 80% power to detect a difference between the disease-free survival (DFS) and overall survival (OS) curves of patients with and without CTCs. The relationships between the OS rate, DFS rate, and *PLS3* expression were analysed by Kaplan--Meier survival curves and log-rank tests. Cox proportional-hazard regression was used to determine multivariate hazard ratios for the OS and DFS rates. The comparison of clinicopathological factors was analysed using Student\'s *t*-tests, *χ*^2^-tests, and analysis of variance. All *P*-values were two-sided, and differences were considered significant when *P*-values were \<0.05. Data were analysed using JMP software v. 10 (SAS Inst. Inc.).

Results
=======

Differential expression of PLS3 in breast cancer cells and blood cells
----------------------------------------------------------------------

First, we examined PLS3/*PLS3* expression in a set of different breast cancer cell lines using western blotting or qRT--PCR ([Figure 1A--D](#fig1){ref-type="fig"}). We also included BC-M1 cells as a DTC cell line derived from the bone marrow of a breast cancer patient, which served as a model for disseminating breast cancer cells ([@bib1]). Samples from healthy individuals were used to the specificity of our marker.

PLS3 protein as well as *PLS3* transcripts were detectable in MDA-MB-231 (E/M phenotype) and Hs578t cells (mesenchymal phenotype; [@bib2], [@bib1]) as well as MCF-7 (luminal phenotype) and MDA-MB-468 (basal phenotype; [@bib2], [@bib1] cells ([Figure 1A--D](#fig1){ref-type="fig"}). Interestingly, very high levels of PLS3 were detected in BC-M1 cells. Thus, PLS3 was expressed in breast cancer cells of different origins and at various stages of the EMT, indicating that PLS3 may be a suitable marker for detecting breast cancer cells.

To assess the specificity of PLS3 as a CTC marker, we analysed its expression in PBMCs from healthy controls ([Figure 1C](#fig1){ref-type="fig"}). PLS3 expression in these cells was below our detection limit in the PBMC fraction. These findings were confirmed by analysing *PLS3* mRNA expression in PBMCs of healthy individuals ([Figure 1D](#fig1){ref-type="fig"}).

Next, we simulated the detection of different CTC subpopulations by immunocytochemistry. For this aim, PB samples from healthy individuals were spiked with breast cancer cells of the MDA-MB-468, SKBR3, and BC-M1 cell lines. Pure blood was used as negative control. We could detect fluorescence signals for PLS3 in all tested cell lines ([Figure 2A](#fig2){ref-type="fig"}). Interestingly, specific signals for PLS3 were observable around the nucleus and in the cytoplasm. Although infrequently, weak signals were rarely detectable that did not belong to the spiked tumour cells ([Figure 2B](#fig2){ref-type="fig"}). In the case of BC-M1 cells, large PLS3-positive cells were detected, which were not observed in unspiked blood samples. Thus, tumour cells were clearly distinguishable from normal blood cells according to differences in PLS3/*PLS3* expression.

Incidence of PLS3-positive CTCs in PB of breast cancer patients
---------------------------------------------------------------

On the basis of our findings and our previous study in colorectal cancer (10), we determined the level of *PLS3* mRNA by qRT--PCR in PB samples as a marker for the presence of CTCs. The cutoff values of *PLS3* were determined by receiver operating characteristic (ROC) curves, which were constructed by plotting all possible pairs in the training set. Sensitivities of *PLS3* were calculated as the ratio of the number of patients with PCR evidence of *PLS3* in PB divided by the number patients who had metastases. Specificities were calculated as the ratio of the number of patients without PCR evidence of *PLS3* in PB divided by the number of patients who did not have metastases. ROC analysis and the optimal cutoff value were calculated as the *PLS3* level that maximised the sensitivity/(1-specificity), as previously described (Yokobori *et al*, 2013).

From the 594 PB samples, 389 (65.5%) breast cancer patients had *PLS3*-positive CTCs, whereas only 9 cases (1.5%) had clinically evident metastatic lesions ([Table 1](#tbl1){ref-type="table"}). Subset analysis revealed that the frequency of *PLS3*-positive cases was significantly elevated in HER2-negative patients (289/414, 69.8%) compared with HER2-positive patients (43/78, 55.1% *P*=0.0313, [Table 1](#tbl1){ref-type="table"}). Subset analyses also revealed that 174 of 229 PgR-negative patients (76%) exhibited PLS3-positive CTCs compared with 143 of 352 PgR-positive patients (41.0%, *P*=0.0008), while the correlation to the ER status was not significant (*P*=0.096). Notably, 74% (54 of 73 patients) of the triple-negative cohort showed *PLS3*-positive CTCs compared with 182 (37.3%) of 488 patients belonging to other breast cancer subtypes (*P*=0.023).

Prognostic relevance of PLS3-positive CTCs
------------------------------------------

PB samples were analysed to elucidate the prognostic value of *PLS3* in breast cancer. We divided samples into training and validation sets in order to perform a cross-validation. Two independent studies comprising 298 patients in the test set and 296 patients in the validation set were performed (total samples *n*=594) in order to assess the reproducibility of our results. Breast cancer patients in both the training set and the validation set presenting positive *PLS3* values had a significantly poorer OS rate than patients with negative values ([Figure 3A and B](#fig3){ref-type="fig"}). In patients without synchronous distant metastasis (TNM stages I--III), those with *PLS3*-positive CTCs in the PB further indicated significantly shorter DFS rates than patients with *PLS3*-negative CTCs in both the training and validation sets ([Figure 3C and D](#fig3){ref-type="fig"}). The influence of *PLS3* expression on OS (*P*=0.0001) and DFS (*P*=0.0003) was also shown in all combined test patients (*n*=594; [Figure 3E and F](#fig3){ref-type="fig"}). In 361 breast cancer cases without lymph node metastasis, *PLS3*-positive patients showed significantly poorer OS and DFS than *PLS3*-negative individuals ([Figure 3G and H](#fig3){ref-type="fig"}). Multivariate analysis revealed that *PLS3* expression in the PB was independently associated with poor OS (hazard ratio (HR)=4.34, *P*=0.0023) and DFS (HR=2.67, *P*=0.0013; [Table 2](#tbl2){ref-type="table"}).

Prognostic relevance of PLS3-positive CTCs in breast cancer subtypes
--------------------------------------------------------------------

Finally, we analysed the long-term prognosis of patients with stages I--III breast cancer according to *PLS3* expression and cancer subtype. Patients with luminal type B or triple-negative-type cancer with *PLS3* expression had significantly poorer DFS ([Supplementary Figure 1B and D](#sup1){ref-type="supplementary-material"}). In terms of OS, *PLS3* expression was significantly associated with poorer survival rates in patients with stages I--III luminal type A or triple-negative type cancer ([Supplementary Figure 2A and D](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In the present study, we demonstrate that PLS3/*PLS3* is a suitable novel marker for the identification of CTCs in breast cancer. In addition, *PLS3*-positive CTCs exhibited prognostic significance in a large training cohort of patients with sufficient follow-up, which was confirmed in an independent validation group. Subset analysis revealed that this new prognostic biomarker was particularly relevant in patients with luminal B and triple-negative subtypes of breast cancer ([@bib10]).

Interestingly, *PLS3* expression was detectable at all stages of the EMT. This finding was confirmed by the analysis of CTCs from breast cancer patients, demonstrating that PLS3 was expressed in CTCs with different EMT stages, including the intermediate stage, which characterises cancer stem cells with a high plasticity ([@bib21]). The specificity of PLS3 as a CTC marker was highlighted by the absence of mRNA and protein expression in PBMCs from healthy controls, therefore PLS3 mRNA is originated from breast cancer cells. As shown in [Figure 2](#fig2){ref-type="fig"}, PLS3 mostly localised in cytoplasm, but partial nuclear localisation was also observed in breast cancer cell lines. Partial PLS3 nuclear localisation was also confirmed in CTC from breast cancer patients (data not shown). As the clinical application of PLS3 as a marker protein was the focus of this work, the biology behind the nuclear localisation of PLS3 remains to be investigated in a future study.

According to our previous work ([@bib9]), we used qRT--PCR as a high-throughput technology for the subsequent prognostic study of large patient cohorts. *PLS3*-positive CTCs were detected in 65.5% of all cases, and 98.5% of these patients were free of overt distant metastases (stages I--III). Compared with other breast cancer studies, this value is at the far upper end of the reported detection rates ([@bib22]). Unlike epithelial differentiation markers, such as CKs ([@bib3]), PLS3 was expressed at higher levels in all breast cancer subtypes and EMT phenotypes, which may explain the high CTC detection rate observed in this study.

For basal-like and triple-negative subtypes, tumour cell plasticity is of special relevance, as these types of cancers frequently undergo some part of the EMT ([@bib7]). Thus, the high detection rate of CTCs in patients with the basal-like or triple-negative phenotype, as demonstrated in the present study, deserves special attention. Using *PLS3* as a CTC marker, we found that 74% of the triple-negative cases were considered to be positive for CTCs.

In addition to the application of *PLS3* as a sole CTC marker, our approach may also have implications for treatment selection and monitoring. Nottingham Prognostic Index (NPI) has been one of the most studied and recognised prognostic index ([@bib5]; [@bib18]). Our study showed that *PLS3* was a significant independent risk factor for survival besides lymph node metastasis and tumour size. Our results did not directly compare the prognostic significance between NPI and *PLS3*, but *PLS3* would be a biomarker of relapse, monitoring and surveillance as well as survival. The present approach may contribute to the selection of high-risk groups of breast cancer patients who require more aggressive systemic therapy to prevent or slow metastatic relapse. In addition, a blood-based marker has the potential for repeated examinations during the course of treatment and after removal of the primary tumour, permitting use in monitoring and for optimising therapeutic strategies.
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###### 

Click here for additional data file.

![**Analysis of PLS3 protein and mRNA levels.** (**A**) Comparison of PLS3 expression in breast cancer cell lines from primary tumours and a DTC cell line from the bone marrow of patients with breast cancer (BC-M1). The lung cancer DTC cell line LC-M1 served as an additional reference for a tumour cell population from a distant site. *α*-Tubulin served as a loading control. (**B**) Quantitative western blot analysis of PLS3 expression in the indicated cell lines. The dimensionless signal intensities are the average of three independent experiments (given as numbers), and vertical error bars indicate s.d. The signal intensities were normalised to the expression of *α*-tubulin. (**C**) Analysis of PLS3 expression in PBMCs from three different healthy control individuals by western blot. The breast cancer cell lines served as a reference for PLS3 expression in breast cancer cells, and *α*-tubulin served as a loading control. We observed lower signal intensities for *α*-tubulin in PBMCs than in the other cell lines. Hence, X-ray films with prolonged exposition times are presented to substantiate that PLS3 expression was below the detection limit in PBMCs. (**D**) Comparison of *PLS3* gene expression between breast cancer cell lines and PBMCs of five different healthy control individuals. Analysis of the housekeeping gene *hprt* confirmed that the analyses for PLS3 provided comparable results between the breast cancer cell lines and the PBMCs. The water control was designated as H20 Cont. Unlike for PLS3 protein, weak signals for *PLS3* mRNA were detected in PBMCs. MDA-231, MDA-MB-231 cells; MDA-468, MDA-MB-468 cells. All experiments: *n*=3.](bjc2015132f1){#fig1}

![**Comparison of PLS3 expression in breast cancer cell lines with PLS3 expression in peripheral blood mononuclear cells of healthy control individuals by immunocytochemical double staining.** Cells of the assigned cell lines were spiked in the blood samples. Identification of the tumour cells was supported by the cytokeratin-specific antibody AE1/AE3. Nuclei were stained with DAPI, and the composite image is an overlay of the DAPI, cytokeratin, and PLS3 images. Two different PLS3 antibodies were applied for the analysis. (**A**) For MDA-MB-468 (MDA-468), an enlarged view of stained cells is shown. (**B**) BC-M1 analysis for PLS3 and blood samples without cell spiking. PLS3 signals in PBMC were labelled with arrows.](bjc2015132f2){#fig2}

![**Prognostic significance of PLS3 expression in breast cancer cases.** Comparison of the OS rate in 298 test sample sets (**A**) and 296 validation sets (**B**) from *PLS3* (+) and *PLS3* (−) breast cancer cases of all stages. Comparison of the DFS rate in 293 test sample sets (**C**) and 292 validation sets (**D**) from *PLS3* (+) and *PLS3* (−) breast cancer cases of stage I--III. In 594 patients (for the analysis of all stages), we compared OS rates between *PLS3* (+) and *PLS3* (−) cases (**E**). DFS was compared in the 585 cases of stage I--III cancers (*PLS3* (+) *vs PLS3* (−) (**F**). OS was compared in 361 cases of all stages and DFS was compared in 359 cases of stages I--III; all cases did not have lymph node metastasis at the time of operation (**G**, **H**).](bjc2015132f3){#fig3}

###### Relationship between peripheral blood PLS3 expression and clinicopathologic factors in breast cancer patients

                                                         **PLS3 negative (***n*=**205)**   **PLS3 positive (***n*=**389)**                
  ----------------------------------------------------- --------------------------------- --------------------------------- ------ ------ --------
  Age (years, mean)                                                   55.7                                                   55.2           0.57
  **T classification**                                                                                                                    
  T1                                                                   91                               31.7                 196    68.3    0.18
  T2                                                                   101                              38.7                 160    61.3      
  T3                                                                   10                               25.6                  29    74.4      
  T4                                                                    3                               42.9                  4     57.1      
  **Lymph node metastasis**                                                                                                               
  Negative                                                             133                              36.8                 228    63.2    0.13
  Positive                                                             72                               30.9                 161    69.1      
  **Venous invasion**                                                                                                                     
  Negative                                                             11                               31.4                  24    68.6    0.69
  Positive                                                             194                              34.7                 365    65.3      
  **Lymphatics invasion**                                                                                                                 
  Negative                                                             74                               32.5                 154    67.5    0.4
  Positive                                                             131                              35.8                 235    64.2      
  **Distant metastasis**                                                                                                                  
  Negative                                                             204                              34.9                 381    65.1    0.1
  Positive                                                              1                               11.1                  8     88.9      
  **Nuclear grade**[a](#t1-fn2){ref-type="fn"}                                                                                            
  Grade1--2                                                            146                              36.1                 258    63.9    0.44
  Grade3                                                               54                               32.7                 111    67.3      
  **Serum CEA**[b](#t1-fn3){ref-type="fn"}                                                                                                
  ≦5 ng ml^−1^                                                         187                              35.2                 345    64.8    0.67
  \>5 ng ml^−1^                                                         8                               27.6                  21    72.4      
  **Serum CA15-3**[c](#t1-fn4){ref-type="fn"}                                                                                             
  ≦30 U ml^−1^                                                         186                              35.2                 342    64.8    0.85
  \>30 U ml^−1^                                                         8                               33.3                  16    66.7      
  **Adjuvant chemotherapy**                                                                                                               
  (−)                                                                  90                               33.5                 179    66.5    0.69
  (+)                                                                  115                              35.4                 210    64.6      
  **Oestrogen receptor**[d](#t1-fn5){ref-type="fn"}                                                                                       
  Negative                                                             52                               32.7                 107    67.3   0.096
  Positive                                                             153                              35.6                 277    64.4      
  **Progesteron receptor**[e](#t1-fn6){ref-type="fn"}                                                                                     
  Negative                                                             55                               24.0                 174    76.0   0.0008
  Positive                                                             143                              40.6                 209    59.4      
  **HER2/neu expression**[f](#t1-fn7){ref-type="fn"}                                                                                      
  0 to 2+                                                              125                              30.2                 289    69.8   0.0313
  3+                                                                   35                               44.9                  43    55.1      
  **Subtype**[g](#t1-fn8){ref-type="fn"}                                                                                                  
  Luminal A                                                            147                              35.3                 270    64.7   0.066
  Luminal B                                                            19                               48.7                  20    51.3      
  HER2                                                                 16                               42.1                  22    57.9      
  Triple negative                                                      19                               26.0                  54    74.0      
  Not determined                                                        4                               20.0                  16    80.0      
  **Anti-hormone therapy**                                                                                                                
  (−)                                                                  55                               27.6                 144    72.4   0.012
  (+)                                                                  150                              38.0                 245    62.0      
  **The site of recurrence**                                                                                                              
  Bone metastasis                                                       5                               35.7                  9     64.3   0.0018
  Lung metastasis                                                       3                               18.8                  13    81.3      
  Local recurrence                                                      2                               18.2                  9     81.8      
  Liver metastasis                                                      1                               10.0                  9     90.0      
  Others                                                                2                                6.7                  28    93.3      
  **Cause of death**                                                                                                                      
  Cancer death                                                          4                               10.5                  34    89.5    0.18
  Non-cancer death                                                      1                               50.0                  1     50.0      

Abbreviations: CA15-3=cancer antigen 15-3; CEA=carcino-embryonic antigen; HER2=human epidermal growth factor receptor 2; PLS3=plastin3.

Information of 25 patients was not available.

Information of 33 patients was not available.

Information of 42 patients was not available.

Information of 5 patients was not available.

Information of 13 patients was not available.

Information of 102 patients was not available.

Information of 7 patients was not available.

###### Univariate and multivariate analysis for survival of peripheral blood PLS3 status and clinicopathological factors in breast cancer patients (*n*=591)

                                 **Disease-free survival**   **Overall survival**                                                                                     
  ----------------------------- --------------------------- ---------------------- ------------------- ---------- -------------------- ---------- ------------------- --------
  PLS3 in PB (high/low)              2.61 (1.46--5.04)              0.0009          2.67 (1.45--5.25)    0.0013    5.47 (2.11--18.6)     0.0002    4.34 (1.63--15.1)   0.0023
  Lymph node metastasis (+/−)        5.75 (3.26--10.8)             \<0.0001         4.53 (2.48--8.83)   \<0.0001    4.91 (2.2--12.4)    \<0.0001   4.21 (1.79--11.6)   0.0007
  Tumour size (⩾2/\<2cm)             2.99 (1.71--5.53)             \<0.0001         2.22 (1.24--4.19)    0.0064    3.97 (1.64--11.8)     0.0014    2.87 (1.16--8.68)   0.021
  ER (+/−)                           0.38 (0.23--0.63)              0.0003                                 NS      0.26 (0.13--0.54)     0.0004    0.45 (0.18--109)    0.076
  HER2 (+/−)                         2.81 (1.56--4.83)              0.0009          2.05 (1.06--3.82)    0.035     1.99 (0.73--4.58)      0.16                           NS
  PgR (+/−)                          0.41 (0.25--069)               0.0006                                 NS      0.24 (0.11--0.51)     0.0002                          NS
  Nuclear grade (3/1--2)             1.94 (1.13--3.26)              0.015                                  NS      0.256 (0.19--5.41)    0.0163                          NS

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; HR=hazard ratio; NS=not significant; PB=peripheral blood; PgR=progesterone receptor; PLS3=plastin3.
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